GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (FRA:7SS) » Definitions » Land And Improvements

Brii Biosciences (FRA:7SS) Land And Improvements : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Land And Improvements?

Brii Biosciences's land and improvements for the quarter that ended in Dec. 2024 was €0.00 Mil.


Brii Biosciences Land And Improvements Historical Data

The historical data trend for Brii Biosciences's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Land And Improvements Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Land And Improvements
Get a 7-Day Free Trial - - - - -

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Brii Biosciences Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Brii Biosciences Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Brii Biosciences Headlines

No Headlines